ADCs for Therapeutic Evaluation

Descriptions

Swansea University Medical School (SUMS) require the Phase 1 development of antibody drug conjugates using two IgG1 murine monoclonal antibodies provided by SUMS to be conjugated to monomethyl auristatin E (MMAE) as payload using an appropriate state of the art linker technology. Following provision of 5mg of Phase 1 ADCs SUMS will evaluate and select the lead candidate for further testing. Upon successful outcome of Phase 1 assessment there will be a requirement for a Phase 2 sytnthesis involving the provision of 200mg of one SUMS selected ADC. If Phase 1 is unsuccessful as determined by evaluation by SUMS, Phase 2 will not be entered into. In addition SUMS require the provision of 12 mg of an isotype control ADC and an Alexa 750 conjugate to the selected SUMS antibody for use in bio-distribution studies. Finally SUMS may require additional small and large scale synthesis over the next 48 months for new IgG1 antibodies.It is expected that the vendor will have a proven record of successful ADC production to standards required for in vivo assessments. In addition the vendor will need to demonstrate the capability for in house ADC assessment and meeting certified safety standards for toxin handling.NOTE: The authority is using eTenderwales to carry out this procurement process. To obtain further information record your interest on Sell2Wales at http://www.sell2wales.gov.wales/search/search_switch.aspx?ID=80076